+++ Zertifikate Award Austria 2020: Stimmen Sie jetzt für den besten Emittenten im Bereich Info & Service ab! +++-w-
29.05.2020 22:50:00

Here's Why Minerva Neurosciences Collapsed Today

Shares of Minerva Neurosciences (NASDAQ: NERV) fell by as much as 86% Friday after the company reported disappointing late-stage results for its lead drug candidate. In a phase 3 trial, roluperidone proved statistically no better than a placebo in treating negative symptoms of schizophrenia. The drug candidate failed to meet both the primary and secondary endpoints of the study. Minerva Neurosciences has three candidates in its pipeline, although only roluperidone and seltorexant have advanced to clinical trials. The outcome of this study is devastating for the development-stage company, although there's an outside chance that roluperidone's prospects can be salvaged. The small-cap stock closed the trading day down 72.5%.Image source: Getty Images.Continue reading
Weiter zum vollständigen Artikel bei "MotleyFool"

Eintrag hinzufügen

Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!

Aktien in diesem Artikel

pagehit